These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9069448)

  • 1. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation.
    Brown JH; Murphy BG; Douglas AF; Short CD; Bhatnagar D; Mackness MI; Hunt LP; Doherty CC; Durrington PN
    Nephron; 1997; 75(3):277-82. PubMed ID: 9069448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy.
    Brown JH; Anwar N; Short CD; Bhatnager D; Mackness MI; Hunt LP; Durrington PN
    Nephrol Dial Transplant; 1993; 8(9):863-7. PubMed ID: 8255521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients.
    Wheeler DC; Morgan R; Thomas DM; Seed M; Rees A; Moore RH
    Transpl Int; 1996; 9(3):221-6. PubMed ID: 8723190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?
    Webb AT; Reaveley DA; O'Donnell M; O'Connor B; Seed M; Brown EA
    Lancet; 1993 Jan; 341(8840):268-70. PubMed ID: 8093917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients.
    Azrolan N; Brown CD; Thomas L; Hayek T; Zhao ZH; Roberts KG; Scheiner C; Friedman EA
    Arterioscler Thromb; 1994 Sep; 14(9):1393-8. PubMed ID: 8068598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early elevation of lipoprotein(a) levels in chronic renal insufficiency.
    De Lima JJ; Maranhão RC; Latrilha Mda C; Diament J; Romão JE; Krieger EM; Pileggi F
    Ren Fail; 1997 Jan; 19(1):145-54. PubMed ID: 9044461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression enhances atherogenicity of lipid profile after transplantation.
    Quaschning T; Mainka T; Nauck M; Rump LC; Wanner C; Krämer-Guth A
    Kidney Int Suppl; 1999 Jul; 71():S235-7. PubMed ID: 10412786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal allograft immunosuppression. IV. Comparison of lipid and lipoprotein profiles in blood using double and triple immunosuppressive drug combinations.
    Isoniemi H; Tikkanen MJ; Ahonen J; Häyry P
    Transpl Int; 1991 Sep; 4(3):130-5. PubMed ID: 1958276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients.
    Raine AE; Carter R; Mann JI; Morris PJ
    Nephrol Dial Transplant; 1988; 3(4):458-63. PubMed ID: 3140134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress in cyclosporin and azathioprine treated renal transplant patients.
    McGrath LT; Treacy R; McClean E; Brown JH
    Clin Chim Acta; 1997 Aug; 264(1):1-12. PubMed ID: 9267698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients.
    Schorn TF; Kliem V; Bojanovski M; Bojanovski D; Repp H; Bunzendahl H; Frei U
    Transpl Int; 1991 Jun; 4(2):92-5. PubMed ID: 1910436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
    Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of lipoprotein A in renal transplant recipients.
    Innocenti M; Lorenzetti M; Naldi F; Paleologo G; Pasquariello A; Marchetti P; Giannarelli R; Rindi P; Navalesi R; Rizzo G
    Transplant Proc; 1998 Aug; 30(5):2048. PubMed ID: 9723386
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation].
    Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM
    Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population.
    Potter JM; McWhinney BC; Sampson L; Hickman PE
    Ther Drug Monit; 2004 Aug; 26(4):408-14. PubMed ID: 15257071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Coronary heart disease and lipoprotein (a): relationship with other lipid cardiovascular risk factors].
    Nogués X; Sentí M; Pedro-Botet J; Molina L; Serrat R; Pons S; Rubiés-Prat J
    Med Clin (Barc); 1992 Feb; 98(5):171-4. PubMed ID: 1532436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplant recipients during cyclosporine and/or azathioprine treatment.
    Allegra A; Corica F; Ientile R; Corsonello A; Sparacino V; Accettola F; Caputo F; Macaione S; Buemi M
    Magnes Res; 1998 Mar; 11(1):11-8. PubMed ID: 9595545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation?
    Schena A; Di Paolo S; Morrone LF; Resta F; Stallone G; Schena FP
    Clin Transplant; 2000 Apr; 14(2):139-46. PubMed ID: 10770419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids.
    Akman B; Uyar M; Afsar B; Sezer S; Ozdemir FN; Haberal M
    Transplant Proc; 2007; 39(1):135-7. PubMed ID: 17275490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose.
    von Ahsen N; Helmhold M; Eisenhauer T; Armstrong VW; Oellerich M
    Eur J Clin Invest; 1996 Aug; 26(8):668-75. PubMed ID: 8872062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.